Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: The Uganda NOHARM sickle cell anemia cohort

Robert O. Opoka, Heather A. Hume, Teresa S. Latham, Adam Lane, Olatundun Williams, Jennifer Tymon, Maria Nakafeero, Phillip Kasirye, Christopher M. Ndugwa, Chandy C. John, Russell E. Ware*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

18 Scopus citations
Original languageEnglish (US)
Pages (from-to)E272-E275
JournalHaematologica
Volume105
Issue number6
DOIs
StatePublished - Jun 1 2020

Funding

Doris Duke Charitable Foundation provided funds for the study (ICRA 2013139) and Addmedica Inc. (Paris, France) donated hydroxyurea (Siklos®) for the NOHARM trial.

ASJC Scopus subject areas

  • Hematology

Cite this